Journal Club

N.54 - Novembre 2024 Matterhorn trial e Reshape - HF 2 trial: Mitraclip per tutti?

N. 52 - Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

N. 49 - Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction

N. 48 - Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality

N. 47 - Novembre 2023 Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial “…caval vincente non si cambia…’’

N. 46 - Novembre 2023 Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation CASTLE Htx “L’elettrofisiologo può contribuire al miglioramento della prognosi di pazienti con scompenso cardiaco end-stage?”

N° 45 - Ottobre 2023 Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study “…non tutte le fibrillazioni atriali sono uguali….?”

N° 44 - Aprile 2023 FRAME-AMI Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease

N°43 - Febbraio 2023 STRONG-HF Trial: Safety, tolerability and efficacy of up titration of guideline-directed medical therapies for acute heart failure

N°42 - Gennaio 2023 DANCAVAS: Danish Cardiovascular Screening Trial